How Long Does TMS Treatment Take? A Course-Length Guide

A full course of TMS for major depressive disorder typically runs six to nine weeks of weekday sessions, with each session lasting about 20 minutes in the chair for intermittent theta-burst stimulation (iTBS) or about 40 minutes for standard 10 Hz repetitive TMS (rTMS), followed by a brief taper. The most common pre-treatment question patients ask before scheduling transcranial magnetic stimulation is how much time the full course will take — per session and across the calendar. The clinical answer has two parts: each session is short, but the course is long — six to nine weeks of near-daily sessions, with a taper at the end. This article walks through the week-by-week timeline, explains why the schedule must be daily, and addresses practical scheduling, what can extend a course, and how insurance shapes the total session count.

The headline numbers

TMS course length for major depressive disorder is standardized by the FDA-cleared protocols described below. A standard acute course is approximately 36 acute-phase sessions delivered five days per week, followed by a taper of three to six additional sessions over two to three weeks. Total elapsed time is typically six to nine weeks.¹

Per-session in-chair time depends on the protocol:

• Intermittent theta-burst stimulation (iTBS): approximately 3 minutes of active stimulation; total in-chair appointment time, including coil positioning and a brief post-session check, typically runs 10–20 minutes.

• Standard 10 Hz repetitive TMS (rTMS): approximately 37.5 minutes of active stimulation; total in-chair appointment time is approximately 40 minutes.

Both protocols are FDA-cleared for the same indication and qualify for insurance coverage; the choice is made by the treating psychiatrist based on tolerability, scheduling, and prior response history.

The full timeline, week by week

The figures below describe a representative course for a patient with treatment-resistant depression on the standard outpatient protocol. Individual courses vary based on tolerability, response trajectory, and the session count authorized by the patient's payer.

Week 0 — evaluation, candidacy, prior authorization

Before any pulse is delivered, the clinic completes three steps. Clinical evaluation with the treating psychiatrist confirms the diagnosis, documents the medication-trial history that establishes treatment resistance, and rules out contraindications — history of seizure, ferromagnetic implants in or near the head, and certain implanted devices. Seizure risk under contemporary safety guidelines is estimated at fewer than 1 per 60,000 sessions.²³ Insurance prior authorization requires documented evidence of failed antidepressant trials (the FDA-cleared indication for TMS requires failure of at least two adequate antidepressant trials in the current episode under most payer policies) and, in many cases, an evidence-based psychotherapy. Scheduling locks in a consistent five-day-per-week appointment slot for the next six to nine weeks. Commercial prior-auth turnaround typically runs 5–15 business days; Medicare Advantage, Medicaid, and Federally-Facilitated Exchange QHPs follow a 7-day standard / 72-hour expedited framework under CMS-0057-F.⁴

Week 1 — motor-threshold mapping plus first treatment

The first session is longer than every session that follows. It includes a one-time procedure called motor-threshold mapping — the calibration step that determines the lowest stimulator output producing a visible thumb or finger twitch when the coil is over the motor cortex. The individualized motor threshold (MT) is used to set treatment intensity, typically at 120% of MT, for the rest of the course.¹ Total chair time on day one is typically 60 to 90 minutes; sessions 2 through 36 return to the protocol-standard runtime.

Weeks 1–4 — acute phase, five sessions per week

The acute phase is the densest portion of the course: five weekday sessions per week, with the goal of producing the cumulative neurophysiological change that drives antidepressant response. No sedation is used. Most patients drive themselves to and from sessions and return to work or normal activity immediately afterward.

Weeks 2–4 — response typically emerges

Response to TMS is gradual and cumulative, not immediate. Most clinical-trial cohorts show measurable improvement starting around weeks two to four, with full response typically assessed at the end of the acute phase.⁵ Early responders — patients with clinically meaningful PHQ-9 or HAM-D reduction by week two — have been described as a recognizable subgroup; early response is associated with, but not required for, eventual remission.⁶ Absence of measurable change by week four does not constitute treatment failure; the bulk of clinical response in routine practice is documented in the second half of the acute phase.

Weeks 7–9 — taper

After the acute phase, sessions step down rather than stopping abruptly. A common taper schedule reduces frequency over two to three weeks — for example, three sessions in the first taper week, two in the second, and one in the third — to consolidate response and reduce the early-relapse rate that has been described when treatment is stopped without a taper.¹ The exact taper schedule is set by the treating psychiatrist.

After the course — maintenance varies

Maintenance protocols after the acute course are not standardized. Some patients enter no maintenance and remain in remission through routine medication management and psychotherapy; others use as-needed booster sessions if symptoms re-emerge. The decision is individualized.

Why the schedule must be daily

Patients frequently ask whether sessions can be spaced to two or three times per week to accommodate work and family. The answer is mechanistic: repetitive TMS is thought to produce its antidepressant effect through cumulative synaptic-plasticity changes analogous to long-term potentiation (LTP) and long-term depression (LTD), the cellular mechanisms underlying learning and memory.⁷ These changes require massed schedules — closely spaced sessions that build on each other before the prior session's effects decay. Sporadic or weekly sessions do not produce the same cumulative cortical change and are not the schedule on which the FDA-cleared evidence base was built. The five-days-per-week schedule is therefore not administrative convenience; it is the protocol that pivotal trials, real-world registries, and the Clinical TMS Society consensus recommendations describe as standard of care.¹

iTBS vs. 10 Hz rTMS — equivalent efficacy, shorter sessions

The per-session time difference between iTBS and standard 10 Hz rTMS compounds to roughly 12 to 18 hours less in-chair time across a 36-session acute phase. The THREE-D trial — a multi-site, randomized non-inferiority trial of 414 patients — established that iTBS produced equivalent response (49% vs. 47%) and remission (32% vs. 27%) compared with 10 Hz rTMS, with no clinically significant difference in tolerability.⁸ The choice between protocols is a clinical and scheduling judgment, not an efficacy trade-off.

What can extend a course

• Non-response at week 4. If no clinically meaningful symptom change is documented at the mid-course assessment, the treating psychiatrist may adjust the protocol — re-mapping coil position, modifying stimulation parameters, or extending the acute phase beyond 36 sessions if clinically indicated and insurance-authorized.

• Missed sessions. Because the protocol depends on closely spaced sessions, missed days are typically made up by extending the calendar rather than skipping.

• Tolerability adjustments. A small subset of patients experience scalp discomfort or treatment-site headache that requires a slower intensity ramp during the first one to two weeks.

• Insurance-driven session-count caps. Prior authorization typically approves a finite number of sessions (often 30–36 for the acute phase plus a defined taper). If additional sessions are clinically warranted, the clinic submits a continued-treatment authorization or appeal; outcomes vary by carrier.

Practical scheduling for working patients

TMS therapy duration is best understood as two numbers held together: short per-session minutes and a long week-by-week calendar. Because sessions are short and unsedated, TMS accommodates full-time employment and caregiving schedules more readily than treatments requiring sedation or recovery time. Common scheduling patterns include early-morning blocks (7:00–9:00 a.m.) before the workday, end-of-day blocks for evening commuters, and lunch-hour slots for iTBS specifically, where the in-chair time fits inside a 45–60 minute break with travel buffer. No driver is required; TMS does not affect alertness or cognition in the way sedated procedures or systemic medications can.

How insurance shapes the total session count

Most major commercial payers and Medicare cover TMS for major depressive disorder under behavioral-health benefits, with prior authorization required.⁹ The prior-auth document typically specifies the maximum sessions approved for the acute phase, the taper structure, and whether maintenance is covered if relapse occurs later. Sessions outside the authorized window may not be reimbursed.

If the clinical course requires more sessions than the initial authorization allows, the standard path is a continued-treatment authorization supported by documented rating-scale data and a letter of medical necessity from the treating psychiatrist. The clinic's insurance team typically handles this workflow on the patient's behalf.

Key takeaways

• A full course of TMS for major depression is typically 36 acute-phase sessions over six to nine weeks, delivered five days per week (Monday through Friday), followed by a taper.

• Per-session in-chair time is approximately 10–20 minutes for iTBS or 40 minutes for 10 Hz rTMS; the THREE-D trial established that both protocols produce equivalent response and remission rates.

• The first session is longer (60–90 minutes) because it includes motor-threshold mapping, a one-time calibration step.

• The daily schedule is mechanistic, not administrative: cumulative synaptic-plasticity changes require massed sessions and do not develop on weekly or sporadic schedules.

• Common reasons a course extends are non-response at week 4, missed sessions, tolerability adjustments, or the need to appeal an initial insurance authorization cap.

• Most major commercial payers and Medicare cover TMS for major depressive disorder with prior authorization; the authorized session count shapes the maximum length of a course.

Patients in Anaheim, Orange County, and the broader 30-mile radius weighing whether the time commitment of a TMS course fits their schedule typically find the answer easier to evaluate once the specifics of their own benefit are clear. The clinic's team confirms the insurance verification details — authorized session count, copay structure, and prior-auth turnaround — before the first session, and the TMS therapy page documents the clinic's approach to candidacy, protocol selection, and the standard six-to-nine-week course described above.

Sources / Further reading

1. Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3):336–346. ↩ ↩ ↩ ↩

2. Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial magnetic stimulation 2012–2016: results of a survey of active laboratories and clinics. Clin Neurophysiol. 2019;130(8):1409–1416. ↩

3. Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021;132(1):269–306. ↩

4. Centers for Medicare & Medicaid Services. Final Rule CMS-0057-F, Advancing Interoperability and Improving Prior Authorization Processes, effective 2026 — establishing 7-day standard and 72-hour expedited prior-authorization decision timeframes for Medicare Advantage, Medicaid, CHIP, and Federally-Facilitated Exchange QHP issuers. ↩

5. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587–596. ↩

6. Feffer K, Lee HH, Mansouri F, et al. Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. J Affect Disord. 2018;236:99–104. ↩

7. Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann Phys Rehabil Med. 2015;58(4):208–213. ↩

8. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683–1692. ↩

9. Centers for Medicare & Medicaid Services. Medicare Coverage Database, Local Coverage Determinations for Transcranial Magnetic Stimulation (e.g., Noridian LCD L34522; Palmetto LCD L34869). There is no National Coverage Determination (NCD) for TMS; coverage is governed by Local Coverage Determinations issued by Medicare Administrative Contractors. ↩